Contents
Results at a Glance
Ozempic 2mg
~11%
avg body weight loss
Wegovy 2.4mg
14.9%
avg body weight loss
Zepbound 15mg
20.9%
avg body weight loss
Zepbound 15mg
63%
lost ≥20% body weight
Results by Drug — Full Trial Data
| Drug | Trial | Duration | Avg % Loss | ≥5% Responders | ≥20% Responders |
|---|---|---|---|---|---|
| Semaglutide 0.5mg (Ozempic) | SUSTAIN-1 | 30 wks | ~4% | ~60% | ~5% |
| Semaglutide 1mg (Ozempic) | SUSTAIN-1 | 30 wks | ~6% | ~70% | ~10% |
| Semaglutide 2mg (Ozempic) | SUSTAIN-FORTE | 40 wks | ~9–11% | ~78% | ~20% |
| Semaglutide 2.4mg (Wegovy) | STEP 1 | 68 wks | 14.9% | 86% | 35% |
| Semaglutide 2.4mg (Wegovy) | STEP 3 (+ lifestyle) | 68 wks | 16.0% | 89% | 40% |
| Tirzepatide 5mg (Zepbound) | SURMOUNT-1 | 72 wks | 15.0% | 85% | 31% |
| Tirzepatide 10mg (Zepbound) | SURMOUNT-1 | 72 wks | 19.5% | 89% | 50% |
| Tirzepatide 15mg (Zepbound) | SURMOUNT-1 | 72 wks | 20.9% | 91% | 63% |
| Tirzepatide 15mg (Zepbound) | SURMOUNT-3 (+ lifestyle) | 72 wks | 26.6% | 94% | ~70% |
💡 SURMOUNT-3's exceptional 26.6% result included a 12-week intensive lifestyle intervention before starting tirzepatide — participants arrived already losing weight. This represents the best-case scenario combining optimal lifestyle with maximum-dose tirzepatide.
Month-by-Month Timeline
Weight loss on GLP-1 medications follows a predictable pattern. Here's what a typical patient on Wegovy or Zepbound experiences:
Month 1
Dose Escalation — Minimal Loss
Starting at the lowest dose (tolerability only). Average loss: 2–4 lbs. Main changes: reduced appetite, some nausea, adjusting to the medication.
Month 2
First Meaningful Progress
Appetite suppression becomes significant. Average cumulative loss: 6–10 lbs. "Food noise" quieting. Clothes may feel slightly looser.
Month 3
Consistent Weekly Losses
Steady 0.5–1.5 lbs/week for most people. Cumulative loss: 10–18 lbs. Energy often improving. GI side effects reducing.
Months 4–6
Major Milestone Zone
Most people reach 10% body weight loss by month 6. Blood pressure, blood sugar, and cholesterol often normalizing. First plateau may occur.
Months 7–12
Continued Progress
Weight loss continues but slows. Cumulative 12–18% body weight loss typical at therapeutic doses. Body composition visibly changed.
Months 12–18
Maximum Effect
Most people reach their maximum weight loss on GLP-1 therapy by month 12–18. Average total: 15–21% depending on drug and dose. Transition to maintenance.
Factors That Affect Your Results
Factors That Increase Weight Loss
- Higher dose: Each dose increase produces meaningfully more weight loss — the 15mg tirzepatide dose produces 40% more loss than the 5mg dose
- Resistance training: People who add strength training lose significantly more fat and preserve more muscle
- Higher protein intake: 1.2–1.6g/kg/day preserves muscle mass and improves body composition beyond what the drug alone produces
- Consistent injections: Never missing a dose maintains stable therapeutic drug levels
- Dietary quality: Reducing ultra-processed foods and sugary drinks compounds the drug's appetite suppression
- Sleep: 7–9 hours of quality sleep significantly improves fat loss
- No diabetes: People without type 2 diabetes consistently lose more weight than those with it on the same GLP-1 dose
Factors That Reduce Weight Loss
- Type 2 diabetes: Reduces average weight loss by approximately 30–40% compared to non-diabetic patients on the same drug and dose
- Certain medications: Antidepressants (especially mirtazapine, paroxetine), antipsychotics, corticosteroids, and some insulin formulations can counteract weight loss
- Hypothyroidism: Untreated or undertreated thyroid disease significantly reduces GLP-1 efficacy
- High stress levels: Elevated cortisol promotes fat storage and can blunt GLP-1 results
- Poor sleep: Under 6 hours significantly reduces fat loss and increases hunger hormones
- Genetic variation: GLP-1 receptor gene polymorphisms affect individual drug response
Real-World vs Clinical Trial Results
Clinical trial results represent outcomes under controlled conditions. Real-world results typically differ:
| Metric | Clinical Trials | Real-World Data |
|---|---|---|
| Average weight loss (Wegovy) | ~15% | ~10–13% |
| Average weight loss (Zepbound) | ~21% | ~14–18% |
| Discontinuation rate at 1 year | ~8–12% | ~30–50% |
| % reaching max dose | ~85% | ~50–60% |
| Duration of use | Structured (68–72 wks) | Often shorter due to cost/access |
⚠️ The biggest real-world gap is medication discontinuation — often due to cost, insurance issues, or side effects. Patients who stay on medication consistently for 12+ months achieve results much closer to clinical trial averages.
Non-Responders — When the Medication Isn't Working
Approximately 10–15% of people are considered GLP-1 non-responders — losing less than 5% of body weight despite reaching a therapeutic dose and using the medication consistently for 16+ weeks.
What to Do If You're Not Responding
- Verify your dose: Confirm you are at a therapeutic dose (at least 0.5mg semaglutide or 5mg tirzepatide) — initiation doses are not therapeutic
- Check adherence: Even one missed dose per month can significantly reduce drug levels and outcomes
- Rule out medical causes: Get thyroid (TSH, free T4), cortisol, and insulin resistance labs
- Review medications: Ask your doctor if any current medications are contributing to weight gain
- Switch drug class: If non-responding on semaglutide, switching to tirzepatide produces a response in many people
- Consider dose increase: If not at maximum dose, escalate and wait 8–12 more weeks
💡 True genetic non-response is rare. Most apparent non-response has an identifiable and addressable cause — medication interactions, undertreated thyroid disease, and insufficient dose being the most common.
Beyond the Scale — Other Benefits
- Blood pressure: Average reduction of 5–7 mmHg systolic — often enough to reduce or eliminate blood pressure medication
- Blood sugar (HbA1c): 1.5–2.3% reduction in diabetic patients — the strongest glycemic control of any non-insulin diabetes medication
- Cholesterol: Meaningful reductions in LDL, triglycerides, and improvements in HDL
- Cardiovascular events: Wegovy reduced major cardiovascular events by 20% in the SELECT trial
- Fatty liver disease: Significant improvement in NAFLD/NASH
- Sleep apnea: Zepbound reduced breathing disruptions in OSA by 63–66% in clinical trials
- Kidney function: Emerging evidence of renoprotective effects in diabetic kidney disease
- Mental health: Many patients report improvements in depression and anxiety alongside weight loss
Frequently Asked Questions
Clinical trials show an average of 8–12% body weight loss on Ozempic at 1–2mg doses over 6–12 months. Real-world results typically range from 6–10%. About 1 in 8 people are non-responders who lose less than 5%.
The STEP 1 trial showed an average of 14.9% body weight loss over 68 weeks. About 35% of participants lost 20% or more. STEP 3 — with an intensive lifestyle component — showed 16% average. Real-world average is typically 10–13%.
The SURMOUNT-1 trial showed an average of 20.9% body weight loss at the 15mg dose over 72 weeks. 63% of participants lost 20% or more, and 36% lost 25% or more. SURMOUNT-3 with a lifestyle lead-in showed 26.6% — approaching bariatric surgery outcomes.
Most people lose 2–5 lbs in the first month during dose escalation, then 0.5–1.5 lbs per week at therapeutic doses. Maximum weight loss is typically reached between months 12–18. Weight loss slows and plateaus as the body adapts.
Approximately 10–15% of people are non-responders, losing less than 5% despite a therapeutic dose for 16+ weeks. Most apparent non-response has an identifiable cause: untreated thyroid disease, weight-promoting medications, insufficient dose, or inconsistent use.